Clayton Partners’s AstraZeneca AZN Stock Holding History

Clayton Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.56M	Buy	23,144 +74	+0.3%	+$14.3K	3.32%	11
2025 Q4	$4.24M	Sell	23,070 -256	-1%	-$44.9K	3.06%	11
2025 Q3	$3.58M	Sell	23,326 -48	-0.2%	-$7.26K	2.71%	17
2025 Q2	$3.27M	Sell	23,374 -2,445	-9%	-$343K	2.74%	15
2025 Q1	$3.8M	Buy	25,819 +2,847	+12%	+$412K	3.3%	10
2024 Q4	$3.01M	Sell	22,972 -142	-0.6%	-$19.9K	2.08%	21
2024 Q3	$3.6M	Sell	23,114 -157	-0.7%	-$25.3K	2.59%	17
2024 Q2	$3.63M	Buy	23,271 +4,834	+26%	+$727K	2.92%	13
2024 Q1	$2.5M	Buy	+18,437	New	+$2.44M	2.12%	22

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Clayton Partners's AZN Position: Q1 2026 in Review

Clayton Partners increased its AstraZeneca (AZN) stake by 0.32% in Q1 2026, buying an estimated $14.3K and bringing the position to 23,144 shares worth $4.56M. The position accounts for 3.32% of the portfolio, ranked #11.

Clayton Partners first reported a position in AZN in Q1 2024 and has held it in 9 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Clayton Partners held 23,144 shares of AstraZeneca worth $4.56M as of Q1 2026.
Clayton Partners bought 74 AstraZeneca shares in Q1 2026, an estimated $14.3K.
AstraZeneca made up 3.32% of Clayton Partners's portfolio in Q1 2026, its #11 holding.
Clayton Partners first reported a position in AstraZeneca in Q1 2024 and has held it in 9 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Clayton Partners's 13F filing for Q1 2026, filed 15 May 2026.